US Pharma Companies Face Revenue Declines from Patent Expirations

This report covers the US prescription pharmaceutical market and how it will be affected by US healthcare reform

Rockville, MD, November 05, 2010 --( has announced the addition of Datamonitor’s new report “US Pharmaceutical Market Overview - Healthcare reform, economic pressures and the patent cliff set to impact Pharma” to their collection of Pharmaceuticals market reports. For more information, visit

The US prescription pharmaceutical market was valued at $279 billion in 2009, with an annual growth rate of 5.5% between 2008 and 2009, having grown at a compound annual growth rate of 5.0% between 2005 and 2009.

The once recession-proof industry is now feeling the impact of the economic downturn. As a result of rising unemployment and the number of uninsured, individuals now face difficult healthcare decisions. Action taken by the US government as part of the reform package to offset the growing healthcare burden will also impact Pharma.

US healthcare reform is set to improve coverage but this will be at the expense of containing healthcare costs. Although the Pharma industry will benefit from the rise in insured individuals, measures such as the increased Medicaid drug rebate and Medicare donut hole discount will have an immediate negative impact on revenues out to 2014.

As a result of the patent cliff beginning in 2011, Pharma is set to lose $42 billion in US branded sales from drugs facing patent expiry between 2011 and 2012. Consequently, US sales for the top 50 pharma companies are forecast to decline by an average of 2.2% year-on-year between 2010 and 2015.

This report enables readers to:

Evaluate the evolving regulatory landscape and how the US healthcare reform is set to impact Pharma out to 2019
Quantify the size and growth of the prescription pharmaceutical market in the US, analyzing key therapy areas, brands and companies
Assess drivers and resistors of generic and biosimilars uptake in the US as well as the level of erosion brands can expect to face post patent expiry

For more information, visit

Veronica Franco

Veronica Franco